Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bacterial type III secretion-based agent T3P-Y058-739

A therapeutic based on a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica that is able to deliver a combination of as of yet undisclosed type I interferons (IFN) and toll-like receptor (TLR) protein payloads, with potential immunomodulating and antineoplastic activities. Upon administration, bacterial type III secretion (T3S)-based agent T3P-Y058-739 may selectively target tumor cells, colonize and deliver the protein payloads into tumor cells. This may activate type I IFN- and TLR-mediated signaling, thereby activating an immune response and killing tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bacterial T3S-based agent T3P-Y058-739
bacterial type III secretion-based protein delivery agent T3P-Y058-739
Yersinia enterocolitica T3S-based protein delivery agent T3P-Y058-739
Yersinia enterocolitica-based therapeutic T3P-Y058-739
Code name:T3P-Y058 739
T3P-Y058-739
T3P-Y058739
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search